Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: A phase I study of the Gynecologic Oncology Group

Paclitaxel 175 mg/m2, carboplatin (AUC = 5) and pegylated liposomal doxorubicin 30 mg/m2 are tolerable without supportive therapy. The usual dose intensity of paclitaxel/carboplatin was maintained by administering liposomal doxorubicin every other cycle.